Although anti-programmed cell death (PD) protein 1 and anti–PD ligand 1 antibodies (PD-[L]1 inhibitors) have shown benefit in several solid tumors, their effect in ovarian cancer remains uncertain. The gene discussed is CD274; the disease is ovarian carcinoma.